Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Classic Follicular Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

Rituximab 11Cyclophosphamide 8ibrutinib 6acalabrutinib 6venetoclax 5fludarabine 4Whole-Body Irradiation 4zanubrutinib 3fludarabine phosphate 3Vincristine 3Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cytarabine 3Cyclosporine 3CT-P10 3Bendamustine Hydrochloride 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Mycophenolic Acid 2Melphalan 2Etoposide 2Dexamethasone 2Calcium Dobesilate 2treosulfan 1palbociclib 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × CT-P10 × 30 days × Clear all
NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
131 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT04765111 2026-05-20

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
53 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
51 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡